Immunotherapy for Esophageal Squamous Cell Carcinoma

被引：57

作者：

Kojima, Takashi ^{[1
]}

Doi, Toshihiko ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

来源：

CURRENT ONCOLOGY REPORTS | 2017年 / 19卷 / 05期

关键词：

Esophageal neoplasms/TH; Immunotherapy; PHASE-II; CHECKPOINT BLOCKADE; DOUBLE-BLIND; CANCER; MULTICENTER; RECURRENT; THERAPY; 5-FLUOROURACIL; LYMPHOCYTES; IRRADIATION;

D O I：

10.1007/s11912-017-0590-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Esophageal squamous cell carcinoma have been frustrating to treat, with slow progress made on extending survival. Immunotherapy targeting immune checkpoints, T cells, and infiltrating lymphocytes has shown promise in early studies. The efficacy of pembrolizumab and nivolumab is encouraging. Anti-chemokine receptors and oncolytic viruses are also making headway against these stubborn tumors; improved results when immune checkpoint inhibitors are combined with radiation therapy are eagerly anticipated. Adoptive T cell therapy and vaccines are also under development. The importance of a multidisciplinary approach cannot be emphasized enough.

引用

页数：8

共 49 条

[1] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[2]

[Anonymous], J CLIN ONCOL S4S

[3]

[Anonymous], 2015, J CLIN ONCOL S

[4]

[Anonymous], J CLIN ONCOL S4S

[5] Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis [J].

Bagnardi, V. ;

Rota, M. ;

Botteri, E. ;

Tramacere, I. ;

Islami, F. ;

Fedirko, V. ;

Scotti, L. ;

Jenab, M. ;

Turati, F. ;

Pasquali, E. ;

Pelucchi, C. ;

Galeone, C. ;

Bellocco, R. ;

Negri, E. ;

Corrao, G. ;

Boffetta, P. ;

La Vecchia, C. .

BRITISH JOURNAL OF CANCER, 2015, 112 (03) :580-593

[6]

Bang YJ, 2010, LANCET, V376, P1302

[7]

Chen K.H., 2016, Oncotarget

[8]

Chen LJ, 2014, INT J CLIN EXP PATHO, V7, P6015

[9] Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial [J].

Crosby, Thomas ;

Hurt, Christopher N. ;

Falk, Stephen ;

Gollins, Simon ;

Mukherjee, Somnath ;

Staffurth, John ;

Ray, Ruby ;

Bashir, Nadim ;

Bridgewater, John A. ;

Geh, J. Ian ;

Cunningham, David ;

Blazeby, Jane ;

Roy, Rajarshi ;

Maughan, Tim ;

Griffiths, Gareth .

LANCET ONCOLOGY, 2013, 14 (07) :627-637

[10] Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice [J].

Deng, Liufu ;

Liang, Hua ;

Burnette, Byron ;

Beckett, Michael ;

Darga, Thomas ;

Weichselbaum, Ralph R. ;

Fu, Yang-Xin .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) :687-695

← 1 2 3 4 5 →